[Use of thymalin in the complex treatment of patients with cancer of the uterus].
Bakhidze. E V EV; Bokhman. Ia V IaV; Khavinson. V Kh VKh; Morozov. V G VG
Key Findings
- Thymalin enhanced T‑cell‑mediated immunity in uterine cancer patients
- Study involved 21 cases receiving thymalin as part of a combined therapy
- Authors recommend thymalin for immune correction if T‑cell immunity is monitored
Practical Outcomes
- For biohackers, the data are very limited and only relate to cancer patients, so it isn’t a ready‑to‑use protocol for healthy people. It hints that thymalin could be explored for immune support, but you’d need clinical‑grade monitoring and more evidence before adding it to longevity or performance regimens.
Summary
A small study of 21 women with uterine cancer added the peptide thymalin to their cancer treatment and saw a noticeable boost in T‑cell immune activity, suggesting it might help correct immune problems when T‑cell levels are tracked.
Abstract
The results of a clinico-immunologic study of thymalin as a component of complex antitumor treatment of 21 cases of cancer of corpus uteri pointed to a pronounced immunomodulating action of the drug on T-cell-mediated immunity. It was inferred that thymalin should be used for immunocorrection in complex treatment for the said neoplasms provided T-cell-mediated immunity is monitored.
Study Information
pubmed
1985